Trial win could drive Acadia's Nuplazid to new use

[cafead]

via Acadia Pharmaceuticals said Monday that it is ending a trial of Nuplazid in dementia-related psychosis early on the recommendation of the study's data-monitoring committee, based on clear signs of effectiveness. The company said it will ask the Food and Drug Administration to add this indication to the product's label in 2020.

article source